HAISHUN(300501) 证券时报网·2024-10-22 07:31Core Viewpoint - Haishun New Materials (300501.SZ) reported a solid performance in Q3 2023, with significant growth in revenue and net profit, indicating strong market positioning in the pharmaceutical packaging sector [1] Financial Performance - For the first three quarters, the company achieved a revenue of 826 million yuan, a year-on-year increase of 9.03% [1] - The net profit attributable to shareholders was 79.72 million yuan, up 5.14% year-on-year, while the net profit excluding non-recurring items reached 74.06 million yuan, marking a 29.81% increase [1] - In Q3 alone, total revenue was 276 million yuan, reflecting a 20.03% year-on-year growth, and the net profit excluding non-recurring items was 24.85 million yuan, up 42.76% [1] - Basic earnings per share stood at 0.42 yuan [1] Industry Outlook - According to Grand View Research, the global pharmaceutical packaging market is expected to reach 127 billion USD by 2024, growing nearly 40% since 2019, with a compound annual growth rate of approximately 7.5% [1] - The domestic market is highlighted as a key area in Asia, benefiting from a large population base, increasing healthcare demands, and government investments in healthcare systems [1] Company Positioning and Innovation - As a leading company in the domestic pharmaceutical packaging sector, Haishun New Materials emphasizes technological innovation, holding 160 patents, including 21 invention patents, and is at the forefront of technology development in high-barrier and recyclable composite materials [1] - The company has accelerated the development of new high-performance products this year, with several products entering testing and review stages, which will enhance its competitiveness in the pharmaceutical packaging market [1] - Some of the company's R&D projects have been recognized as key projects in Suzhou, reflecting its strength and recognition in technological innovation [1] Market Expansion and Partnerships - The company has successfully expanded its domestic and international markets, establishing a broad sales network and maintaining good relationships with over 80 of the top 100 domestic pharmaceutical companies [1] - Haishun New Materials has received high recognition from well-known pharmaceutical companies, including Pfizer, AstraZeneca, Huahai Pharmaceutical, and Federal Pharmaceutical, further enhancing its brand influence [1] Dividend Announcement - The company announced a cash dividend plan for the first three quarters, proposing to distribute 2.7 yuan per 10 shares (including tax), totaling 50.85 million yuan, which is a historical high [1] - Since its listing in 2016, Haishun New Materials has conducted 10 cash dividend distributions, with a cumulative net profit of 797.50 million yuan and total cash dividends amounting to 246.38 million yuan, resulting in a dividend payout ratio of 30.89% [1]